Curis (CRIS) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
25 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed stockholders and outlined the agenda and rules of conduct for the virtual special meeting.
The meeting was recorded, and validated stockholders were invited to submit questions about the proposals.
Legal counsel and all directors participated telephonically.
Specific resolutions to be voted on
Proposal to amend the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25, at the board's discretion.
Proposal to adjourn the meeting to a later date if necessary to solicit more proxies for the reverse stock split.
Corporate governance
Inspector of Election from Broadridge Financial Solutions was appointed to oversee voting and quorum.
Quorum was established with 27,773,949 shares represented out of 38,978,693 outstanding.
Latest events from Curis
- Net loss increased, cash runway is short, and additional funding is urgently needed to sustain operations.CRIS
Q2 2026 - Best-efforts offering seeks up to $13.6M for R&D, but going concern risk and dilution remain high.CRIS
Registration filing - Emavusertib delivers superior efficacy and safety in hematologic cancers, advancing toward approval.CRIS
Corporate presentation - Emavusertib plus BTKi achieves strong PCNSL responses and advances, pending further funding.CRIS
Study update - Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing - Q3 net loss narrowed, emavusertib data positive, but funding needed beyond mid-2025.CRIS
Q3 2024 - Emavusertib gains EU ODD as Q2 net loss hits $11.8M and cash runway extends into Q1 2025.CRIS
Q2 2024 - Emavusertib advances on accelerated approval path with strong data, improved financials, and funding risks.CRIS
Q4 2024